HCLTech launches suite of technology solutions for 5G and beyond
HCLTech, a leading global technology company, launched a range of innovative technology solutions for the 5G ecosystem at the Mobile World Congress 2023.
HCLTech’s solutions leverage its differentiated portfolio across digital, engineering, cloud and software to help communication service providers (CSPs) and enterprises supercharge their 5G readiness and accelerate monetization of their investments.
5G system integration framework (5G SF)
HCLTech’s 5G SF enables operators of public and private 5G to seamlessly deploy and integrate critical components of a future-ready network. With HCLTech’s 5G SF, CSPs, enterprises, hyperscalers, chip and equipment manufacturers will benefit from seamless virtual functions onboarding, significant operational efficiencies and enhanced network and user experiences.
“Communication service providers and enterprises need a system integration partner that can scale in diverse technology domains to integrate, deploy and operate 5G networks. With our 5G system integration framework, we have created a differentiated set of services to address the unique system integration requirements for disaggregated and distributed network domains that include RAN, transport and core,” said Vijay Guntur, President and Head, Engineering and R&D Services, HCLTech.
According to Jagdeshwar Gattu, President, Digital Foundation Services, HCLTech: “HCLTech’s heritage in architecture and design, system integration and management of complex networks across different technologies makes us a perfect partner for CSPs and enterprises aiming to achieving business outcomes by deploying industry-specific 5G use cases.”
CloudSMART Modernization Experience and Site Reliability Engineering (SRE)
With the onset of 5G, the CSPs are looking to rapidly transition from proprietary platforms to Cloud Native platforms, which provide flexibility and scalability to deliver customized services to users.
HCLTech’s innovative CloudSMART Modernization Experience for telecom supports the adoption of open-source and off-the-shelf IT vendor solutions. This gives telecom service providers the flexibility of developing tailored solutions by combining best-of-breed platforms from multiple network solutions providers.
HCLTech’s SRE enablement for Cloud Native telecom enables a complete set of practices required to successfully run telecom operations at scale using modern Cloud Native platforms. It allows telecom service providers to improve and maintain industry-best reliability levels through implementing advanced SRE practices within their operations, ultimately gaining efficiencies while reducing lock-in with traditional telecom network providers.
“We are thrilled to be launching these two new services to transform the ways in which enterprises across industries view their strategies for business growth and development,” said Kalyan Kumar, Chief Technology Officer, Head of Ecosystems and Chief Product Officer, Products and Platforms, HCLTech. “Our enablement of Cloud Native telecommunications platforms will provide a much-needed solution for businesses looking to take advantage of the latest advancements in the telecommunications industry.”
Ecosystem collaboration for network modernization
HCLTech in collaboration with Dell Technologies will provide network modernization solutions to CSPs and enterprises. HCLTech will provide end-to-end system integration services for vRAN (virtualized radio access networks), ORAN (open radio access networks), private 5G networks and edge/multi-access edge computing deployments, including telecom network transformation, design, interoperability, optimization and managed services. Dell Technologies will help CSPs modernize their network infrastructure to transform service delivery and simplify operations by performing platform integration services, including implementing engineered telecom cloud platforms, testing, automation and orchestration. Dell will also provide carrier-grade support and managed services designed for telecom operators and enterprises.
Learn more at https://www.hcltech.com/events/mwc-barcelona
About HCLTech
HCLTech is a global technology company, home to 222,000+ people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending December 2022 totaled $12.3 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005461/en/
Contact information
Americas
Michelle Rico michelle.rico@hcl.com
EMEA
Elka Ghudial elka.ghudial@hcl.com
ANZ
James Galvin james.galvin@hcl.com
India and APAC
Devneeta Pahuja devneeta.p@hcl.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom